Insulet Announces Appointment of Jonathan J. Mazelsky to its Board of Directors
Insulet Corporation (NASDAQ: PODD) (Insulet or the Company), the global leader in tubeless insulin pump technology with its Omnipod® brand of products, today announced the appointment of Jonathan (“Jay”) Mazelsky to the Company’s Board of Directors, effective July 1, 2026. Mr. Mazelsky joins the Board as an independent director.
“We are pleased to welcome Jay to Insulet’s Board of Directors,” said President and CEO Ashley McEvoy. “Jay has a strong track record of translating science into solutions to drive growth and create significant and enduring shareholder value. His background and expertise will be integral as Insulet continues to expand access and further strengthen Omnipod’s leadership position. We look forward to working with Jay and leveraging his insights to help advance our mission focused on transforming the lives of people with diabetes around the world.”
“I’m honored to join Insulet’s Board at such an exciting time in the Company’s growth journey,” said Jay Mazelsky. “Insulet has built a strong category-leading business based on Omnipod’s unique AID system, clinical evidence and real-world outcomes, and I am truly inspired by the Company’s relentless commitment to reduce the burden of diabetes. I look forward to working with Ashley, the Board, and the executive leadership team as Insulet continues to build on its momentum and deliver stakeholder value.”
